Video

Dr. Champlin on the Role of EASIX Following Allogeneic Stem Cell Transplant

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

Richard E. Champlin, a professor of medicine at The University of Texas MD Anderson Cancer Center, discusses the association reported between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent allogenic stem cell transplantation (SCT).

Grade ≥2 fluid overload has been determined to be a significant adverse event with nonrelapse mortality in patients with allogenic SCT, and researchers hypothesized that endothelial damage to prior treatments before receiving allogenic SCT can be associated with this type of toxicity. In the study, predictors of ≥2 fluid overload and 6-month overall survival were evaluated, as well as EASIX scores.

Findings showed that an elevated EASIX index can identify a group of patients who are at high risk for treatment-related mortality, Champlin explains. By identifying these patients, physicians can introduce interventions that can reduce fluid and improve capillary gut syndrome. There are agents available that could reduce fluid overload appropriately in this high-risk group, he concludes.

<<< 2019 Transplantation and Cellular Therapy Meetings

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School